Thalidomide inhalation - Vicore Pharma
Alternative Names: Inhaled IMID; VP-02Latest Information Update: 09 May 2024
At a glance
- Originator INIM Pharma
- Developer Vicore Pharma
- Class Antifibrotics; Antileprotics; Antineoplastics; Antitussives; Immunotherapies; Indoles; Phthalimides; Piperidones; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cough; Idiopathic pulmonary fibrosis
Most Recent Events
- 03 May 2024 Discontinued - Preclinical for Cough in Sweden (Inhalation)
- 03 May 2024 Discontinued - Preclinical for Idiopathic pulmonary fibrosis in Sweden (Inhalation)
- 28 Mar 2024 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in Sweden (Inhalation)